

**April 16, 2025**

***AmeriHealth Caritas Next Formulary GLP-1 Medications***

AmeriHealth Caritas Next formulary GLP-1 medications (Mounjaro, Ozempic, Rybelsus, Trulicity) are updating from requiring a step therapy with Metformin to a prior authorization requiring the following:

**Initial authorization:**

- Diagnosis of Type 2 Diabetes Mellitus
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert
- Documentation of laboratory results that meet one of the following values:
  - o A1C  $\geq 6.5$
  - o Fasting plasma glucose (FPG)  $\geq 126\text{mg/dL}$
  - o 2-hour plasma glucose (PG)  $\geq 200\text{ mg/dL}$  during OGTT (oral glucose tolerance test)
  - o Random Plasma Glucose  $\geq 200\text{ mg/dL}$

**Reauthorization:**

- Documentation of positive clinical response to therapy (e.g., A1C lab results)
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert

The above prior auth criteria is effective 4/15/2025 for new starts and 7/1/2025 for our current members on a GLP-1 medication.

If you have any questions, please reach out to AmeriHealth Caritas Next Pharmacy Services at 1-833-981-7967.